leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   807 Trials   807 Trials   14372 News 


«12...678910111213141516...235236»
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
    Trial completion date, Trial primary completion date, Metastases:  NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer (clinicaltrials.gov) -  Sep 19, 2024   
    P2,  N=44, Recruiting, 
    Trial completion date: Dec 2026 --> Apr 2027 | Trial primary completion date: Jun 2026 --> Oct 2026 Trial completion date: Jul 2024 --> Dec 2025 | Trial primary completion date: May 2024 --> Apr 2025
  • ||||||||||  SSGJ-707 / 3SBio
    Enrollment open, Metastases:  A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) -  Sep 19, 2024   
    P2,  N=130, Recruiting, 
    Trial completion date: Jul 2024 --> Dec 2025 | Trial primary completion date: May 2024 --> Apr 2025 Not yet recruiting --> Recruiting
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Case report: Management of Early-Stage Colorectal Cancer (CRC) Patients with tissue free Minimal Residual Disease (MRD) (Exhibition area) -  Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1106;    
    Conclusions The two-weekly TPF regimen demonstrated significantly better response rates and lower toxicity compared to the three-weekly TPF regimen, making it a viable alternative in high-prevalence countries like India. Using tissue-free MRD assessment in routine clinical practice can supplement standard-of-care procedures to determine prognosis and guide therapeutic decisions in patients with early stage CRC.
  • ||||||||||  Vectibix (panitumumab) / Amgen
    Confronting Dual Fronts: Management of Lupus Nephritis, Advanced Colon Cancer, and Nephrotoxicity in the Emergence of Nephro-Oncology (Exhibition area) -  Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1094;    
    Case summary We present the case of a 42-year-old woman with a long-standing history of SLE and Class III lupus nephritis, who achieved remission with cyclophosphamide but developed CKD (baseline creatinine clearance 40 mL/min)...The treatment intent was palliative, initiating FOLFOX chemotherapy with a 25% oxaliplatin dose reduction and standard anti-emetic premedication...Molecular testing revealed KRAS wild type, allowing a switch to 5-FU chemotherapy combined with the anti-EGFR agent panitumumab...Standard chemotherapy with moderate emetogenic potential posed significant challenges, impacting renal function. A personalized approach and a deeper understanding of nephro-oncology are warranted to optimize treatment in such patients.
  • ||||||||||  Case Report: Successful Continuation of Treatment with BRAF Inhibitors After Treatment Modification for Serous Retinal Detachment in BRAF V600E-Mutated Metastatic Colorectal Cancer (Exhibition area) -  Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1093;    
    According to BEACON CRC study, encorafenib(E)+binimetinib(B)+cetuximab(C) or E+C resulted in longer overall survival than standard chemotherapy in 2nd line treatment...She was treated with capecitabine and oxaliplatin as adjuvant therapy...FOLFOXIRI+bevacizumab was administered as 1st line treatment, and the tumor marker was elevated within four months...Conclusion We present a case of BRAF V600E-mutated mCRC that was successfully treated with E+C following the occurrence of serous retinal detachment associated with E+B+C. This case highlights the potential for treatment modification to manage side effects and continue effective cancer therapy.
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
    Current trends in treatment regimens and overall survival for patients with advanced pancreatic cancer in a real-world setting (Exhibition area) -  Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_603;    
    Background Over the past seven years in Japan, targeted therapies based on comprehensive genomic profiling have been increasingly used for advanced pancreatic cancer (PC), and nanoliposomal irinotecan combined with fluorouracil/folinic acid (nal-IRI+5-FU/LV) has been approved as a second-line therapy...The most widely used regimen as first-line treatment was gemcitabine plus nab-paclitaxel (GnP) (71.4%), followed by modified FOLFIRINOX (13.1%), and targeted or investigational therapy (6.4%)...Conclusions Despite the approval of novel treatments, their impact on the survival outcomes of all PC patients remains limited. In the treatment of PC, the difficulty in transitioning to second-line treatment and the lack of targeted therapy options may prevent significant improvement in prognosis.
  • ||||||||||  Safety and efficacy of XELOXIRI regimen in patients with unresectable pancreatic ductal adenocarcinoma (Exhibition area) -  Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_597;    
    Capecitabine, an oral prodrug of fluorouracil, offers a convenient and safe alternative...All Grade 4 TRAEs were neutropenia, with no Grade 5 TRAEs or deaths. Conclusions The XELOXIRI regimen demonstrates significant efficacy and manageable toxicity in treating UPDA, providing a convenient alternative to FOLFOXIRI.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with portal vein tumor thrombosis (PVTT) treated with camrelizumab, apatinib plus FOLFOX chemotherapy (Exhibition area) -  Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_560;    
    P2
    The most common TEAEs was platelet count decreased (10 [41.7%]), and Grade ?3 TEAEs occurred in 13 pts (54.2%). Table: 215P ALL (n=35) PVTT-Vp0 (n=11) PVTT-Vp1-3 (n=12) PVTT-Vp4 (n=12) Response evaluation (Per RECIST v 1.1) ORR (%) 60.0 54.5 58.3 66.7 DCR (%) 97.1 100.0 91.7 100.0 PFS-6 incidence (%) 88.5 90.9 83.3 91.7 PFS-9 incidence (%) 76.1 80.8 74.1 74.1 PFS-12 incidence (%) 55.1 80.8 28.2 55.6 the median time for PFS (mon) 15.5 NR 10.8 13.7 OS-12 incidence (%) 76.6 90.0 67.5 73.3 the median time for OS (mon) NR NR 14.3 NR Response evaluation (Per mRECIST) ORR (%) 68.6 54.5 66.7 83.3 DCR (%) 100.0 100.0 100.0 100.0 Safety evaluation (Per CTCAE v5.0) Grade <3 TEAEs incidence (%) 100.0 100.0 100.0 100.0 Grade ?3 TEAEs incidence (%) 48.6 36.4 33.3 75.0 Conclusions In pts for HCC with PVTT, especially Vp4, better survival can be achieved through combination therapy, which is worthy of clinical application.
  • ||||||||||  Positivity rates of FGFR2 fusion gene or rearrangement and genetic profiling in Asian Cholangiocarcinoma (Exhibition area) -  Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_494;    
    P
    Although gemcitabine plus cisplatin and an immune checkpoint inhibitor is the standard first-line palliative chemotherapy and FOLFOX is the second-line option, the efficacy remains limited and requires improvement...Conclusions The positivity of FGFR2 fusion was slightly lower in the Asian region. However, consistent with previous reports, it was more common in younger ICC patients.
  • ||||||||||  Cyramza (ramucirumab) / Eli Lilly, Avastin (bevacizumab) / Roche
    FOLFIRI plus bevacizumab versus FOLFIRI plus ramucirumab as second-line chemotherapy for metastatic colorectal cancer in the real-world (Exhibition area) -  Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_447;    
    Background Bevacizumab (BV) or Ramucirumab (RAM) combining with FOLFIRI (infusional 5-fluorouracil, leucovorin and irinotecan) improves progression-free survival (PFS) and overall survival (OS) in second-line chemotherapy for patients with metastatic colorectal cancer (mCRC)...Methods We retrospectively identified 95 Patients who received either FOLFIRI+BV (n = 49) or FOLFIRI+ RAM (n = 46) as second-line chemotherapy after progression during fluoropyrimidine plus oxaliplatin, from 2016 to 2023 at Nagoya City University Hospital...The frequency of hypertension and proteinuria grade 3 was 0% and 2% in FOLFIRI+BV, but 13% and 13% in FOLFIRI+RAM. Conclusions FOLFIRI+BV and FOLFIRI+RAM showed similar anti-tumor activity in second-line treatment for mCRC although RAM may be related to incidence of hypertension and proteinuria.
  • ||||||||||  A multi-centre analysis of metastatic colorectal cancer diagnosed under the age of 35: A molecularly distinct group? (Exhibition area) -  Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_438;    
    VYP and YP were similarly likely to receive chemotherapy (94% vs 92%, p=0.65), and FOLFOXIRI (17% vs 13%, respectively, p=0.23)...Table: 84P Molecular data and testing rates since 2015 Variable YP (N=382) VYP (N=102) OP (N=2293) p-value (VYP vs YP) p-value (VY vs OP) MSI ustable/ MMR deficiency N (%) 11 (3.1) 8 (9.1) 120 (6.7) 0.03 0.54 Testing rate, % 92 86 78 BRAF V600E mutation N (%) 36 (11) 30 (36) 210 (13) <0.001 <0.001 Testing rate, % 86 82 71 BRAF mutation and pMMR N (%) 35 (11) 26 (32) 139 (8.7) <0.001 <0.001 Testing rate, % 86 80 70 RAS mutation N (%) 172 (50) 33 (38) 881 (49) 0.05 0.05 Testing rate, % 90 84 78 Conclusions In our analysis, patients aged under 35 years appear to represent a distinct subset of early onset mCRC, with increased rates of synchronous disease, BRAFmt and dMMR cancers compared versus those aged 35-50 at presentation. There were no significant differences in survival outcomes for VYP and YP.
  • ||||||||||  Vectibix (panitumumab) / Amgen, Lumakras (sotorasib) / Amgen
    Sotorasib (soto), panitumumab (pani), and FOLFIRI in first-line (1L) KRAS G12C (Hall 404) -  Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_215;    
    P1, P3
    Conclusions The combination of soto, pani, and FOLFIRI in the 1L setting had a tolerable safety profile and a promising response rate in pts from Japan and ROW. The phase III CodeBreaK 301 (NCT06252649) study is currently enrolling to evaluate this combination against standard of care in 1L mCRC.
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Clinical, Journal:  Persistent Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Rectal Cancer. (Pubmed Central) -  Sep 12, 2024   
    In this cohort study, PLNM unmasked an unfavorable phenotype of rectal cancer at high risk for treatment failure. More aggressive adjuvant treatment might be considered; however, risk-adapted surveillance strategies and early recurrence-directed surgery, if feasible, are important strategies in this group of patients with CRT- and/or chemotherapy-resistant disease.
  • ||||||||||  Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
    Journal, PD(L)-1 Biomarker, Metastases:  First line therapy in stage IV BRAF mutated colorectal cancer. (Pubmed Central) -  Sep 12, 2024   
    More aggressive adjuvant treatment might be considered; however, risk-adapted surveillance strategies and early recurrence-directed surgery, if feasible, are important strategies in this group of patients with CRT- and/or chemotherapy-resistant disease. CT doublet
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
    Biomarker, Journal, Metastases:  Biomarker-stratified first-line treatment of right-sided metastatic colon cancer with interdisciplinary collaboration in the IVOPAK II trial. (Pubmed Central) -  Sep 11, 2024   
    All-RAS-wildtype: n ?=?5 (20%): received systemic first-line treatment: FOLFIRI plus cetuximab...Complete response: n?=?0, partial response: n?=?14 (56%), stable disease: n?=?8 (32%), progressive disease: n?=?3 (12%), early tumor shrinkage: n?=?13 (52%), estimates progression-free survival: 13?months (95% CI 8-17?months), estimated OS: 48?months (95% CI 25-71?months), median follow-up: 26?months (1-61?months), no evidence of disease: n?=?4 (16%). A chemotherapy doublette regimen with FOLFIRI plus a biological as first-line treatment shows promising efficacy and secondary metastatic resection after interdisciplinary discussion was associated with a survival benefit in right-sided metastatic colon carcinoma.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    CHECK YOURSELF BEFORE YOU WRECK YOURSELF: A CASE OF PEMBROLIZUMAB-INDUCED PNEUMONITIS (Convention Center Exhibit Hall: Poster Area 3) -  Sep 11, 2024 - Abstract #CHEST2024CHEST_6423;    
    If recognized early and treated appropriately, the vast majority of patients recover. Unfortunately, patients with multiple comorbidities or poor functional baseline may not do as well or may need additional treatment such as IVIG or biologics such as rituximab.
  • ||||||||||  oxaliplatin / Generic mfg.
    Journal:  Oxaliplatin-Induced Immune Thrombocytopenia in a Patient with Pancreatic Cancer. (Pubmed Central) -  Sep 9, 2024   
    (ClinicalTrials.gov: NCT02352337). Oxaliplatin-induced immune thrombocytopenia is a rare but potentially life-threatening side effect of chemotherapy.Management of drug-induced immune thrombocytopenia involves discontinuation of the offending drug and the use of steroids.Monitoring and follow-up are crucial in patients receiving oxaliplatin-based chemotherapy to promptly detect and manage potential hematologic emergencies, including immune thrombocytopenia.
  • ||||||||||  GSK5764227 / GSK
    Enrollment change:  A Study of GSK5764227 in Participants With. Advanced Solid Tumors (clinicaltrials.gov) -  Sep 8, 2024   
    P1,  N=260, Not yet recruiting, 
    Oxaliplatin-induced immune thrombocytopenia is a rare but potentially life-threatening side effect of chemotherapy.Management of drug-induced immune thrombocytopenia involves discontinuation of the offending drug and the use of steroids.Monitoring and follow-up are crucial in patients receiving oxaliplatin-based chemotherapy to promptly detect and manage potential hematologic emergencies, including immune thrombocytopenia. N=100 --> 260
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Journal:  Familial adenomatous polyposis: a case report. (Pubmed Central) -  Sep 8, 2024   
    N=100 --> 260 In the clinical evaluation of a patient with rectal bleeding, familial adenomatous polyposis must be considered as a differential diagnosis in subjects having family history of colonic adenocarcinoma for early diagnostic workup, management, family genetic counseling, and testing.